Market News & Trends
Allena Pharmaceuticals Achieves Alignment With FDA on Phase 3 Program
Allena Pharmaceuticals, Inc. recently announced it has reached alignment with the US FDA on both the design of URIROX-2, its second pivotal Phase 3 trial…
Outlook Therapeutics Closes Third Tranche of $20-Million Private Placement for Clinical Trials
Outlook Therapeutics, Inc. recently announced it closed on the third tranche (of four) of its $20-million private placement of common stock to BioLexis Pte. Limited,…
Cybrexa Therapeutics Selects Lead Clinical Candidate to Treat Various Solid Tumors in Combination With Chemotherapy
Cybrexa Therapeutics recently announced it has selected CBX-11 as its lead clinical development candidate for the treatment of patients with various solid tumors.
Fujifilm Commits to Further Research on Nucleic Acid-Liposome Drug Delivery System
FUJIFILM Corporation recently announced that it is working toward improving the development of nucleic acid therapeutics by using liposomal drug delivery systems.
R&D Returns Fall to Lowest Level in 9 Years
Projected returns on investment in research and development (R&D) for the top 12 biopharmaceutical companies have fallen to 1.9%, according to a study by Deloitte’s Centre for Health Solutions leveraging revenue forecasts and industry benchmarks generated by GlobalData, a leading data and analytics company.
Experic Launch Marked by Announcement of Plans for State-of-the-Art cGMP Pharmaceutical Supply Services Facility
Experic, a high-quality pharmaceutical supply services provider, marked its official launch by announcing it has leased a 45,500 square foot, state-of-the-art Class A research, manufacturing and packaging facility located at 2 Clarke Drive in Cranbury, NJ, the heart of the state’s pharmaceutical belt.
Croda Acquires Biosector; Strengthens Pharmaceutical Offering
Croda International Plc, the speciality chemical company that creates high performance ingredients and technologies relied upon by industry and consumers globally, recently announced that it has strengthened its pharmaceutical offering by signing a definitive agreement with Brenntag Nordic A/S to acquire Brenntag Biosector (Biosector).
Histo-Scientific Research Laboratories & Vet Path Services Merge
Histo-Scientific Research Laboratories, Inc. (HSRL), has completed its merger with Vet Path Services (VPS) to create the leading provider of research and pre-clinical histology, pathology,…
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data; Initiates Pivotal Phase 3 Clinical Trial
Kiniksa Pharmaceuticals, Ltd.recently announced interim data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and…
SunGen Pharma Receives Its Second & Third ANDA Approval from US FDA
SunGen Pharma recently announced it has received its second and third ANDA approval from the US FDA. The second ANDA is Amphetamine Salts, a generic…
Intensity Therapeutics Strengthens Intellectual Property Portfolio With Issuance of Several New Patents
Intensity Therapeutics, Inc. recently announced the receipt of patents protecting the company’s technology and its lead product candidate, INT230-6, in China, Japan, Korea, Russia, and…
Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial
Aravive, Inc. recently announced the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care…
Entera Bio & Amgen Enter Strategic Research Collaboration
Entera Bio Ltd. recently announced it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera…
Y-mAbs Therapeutics Announces FDA Clearance of IND
Y-mAbs Therapeutics, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a humanized bispecific GD2 antibody.
Quotient Sciences & Druggability Technologies Announce Collaboration
Quotient Sciences and Druggability Technologies recently announced a collaboration to utilize Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT.
Cambrex Expands Analytical Capabilities
Cambrex Corporation recently announced it is investing $1 million at its High Point, NC, site to fit out 1,300 sq ft of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project.
Translate Bio Expands Patent Portfolio With Newly Issued US Patent Relating to its mRNA Therapeutics Platform
Translate Bio recently announced that the USPTO has issued US Patent No. 10,143,758, Liver Specific Delivery of Messenger RNA, which builds on the company’s 2009 patent filing…
RedHill Biopharma Announces Positive Top-Line Results From Confirmatory Phase 3 Study
RedHill Biopharma Ltd. recently announced positive top-line results from the ERADICATE Hp2 study, a two-arm, randomized, double-blind, active comparator-controlled, confirmatory Phase 3 study with TALICIA (RHB-105) for H.…
MilliporeSigma Signs Exclusive Agreement With BioDuro
MilliporeSigma has signed a supply and OEM agreement with BioDuro, LLC, on exclusive terms, for worldwide distribution of AISF ([4-(Acetylamino)phenyl]-ImidodiSulfuryl diFluoride), a convenient, shelf-stable, crystalline…
Sienna Biopharmaceuticals Announces Topical Drug Study Results
Sienna Biopharmaceuticals, Inc. recently announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the company’s lead drug candidate developed using its proprietary Topical…
